Ibrance for sarcoma – pro
As far as I can tell there are two sarcoma studies, both Phase II.IN one, more than 90 percent of well-differentiated or dedifferentiated liposarcomas (DDLPS) have amplification of cyclin-dependent kinase 4 (CDK4), and a modest degree of benefit from the selective CDK4/CDK6 inhibitor palbociclib was suggested in a phase II open label trial (one complete response among 35 assessable patients, 12-week PFS 57 percent).In another study, the activity of palbociclib, a CDK4/CDK6-inhibitor currently approved in breast cancer, in CDK4-positive WDLS/DDLS was shown in a phase 2 study reporting a 12-week PFS rate of 66%.
Dickson MA, Schwartz GK, Keohan ML, D’Angelo SP, Gounder MM, Chi P, Antonescu CR, Landa J, Qin LX, Crago AM, Singer S, Koff A, Tap WD, Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.
SOJAMA Oncol. 2016 Jul;2(7):937-40.
ickson MA, Tap WD, Keohan ML, D’Angelo SP, Gounder MM, Antonescu CR, Landa J, Qin LX, Rathbone DD, Condy MM, et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol. 2013;31:2024–8.
Perez M, Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA. Oncotarget. 2015 Dec 1;6(38):40557-74. doi: 10.18632/oncotarget.5829.